Hanson Jarom E, Birdsall Elisabeth, Seferian Kristi S, Crosby Marcus A, Keefe Kristen A, Gibb James W, Hanson Glen R, Fleckenstein Annette E
Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Room 201, Salt Lake City, UT 84112, USA.
Eur J Pharmacol. 2009 Apr 1;607(1-3):68-73. doi: 10.1016/j.ejphar.2009.01.037.
Repeated high-dose methamphetamine administrations can cause persistent dopaminergic deficits. As individuals abusing methamphetamine are often exposed to recurrent high-dose administration, the impact of its repeated exposure merits investigation. Accordingly, rats were pretreated with repeated high-dose injections of methamphetamine, and subsequently "challenged" with the same neurotoxic regimen 7 or 30 days later. Results revealed that the initial methamphetamine treatment caused persistent deficits in striatal dopamine levels, dopamine transporter function, and vesicular monoamine transporter-2 function. The subsequent methamphetamine challenge treatment was without further persistent effects on these parameters, as assessed 7 days after the challenge, regardless of the interval (7 or 30 days) between the initial and challenge drug exposures. Similarly, a methamphetamine challenge treatment administered 7 days after the initial drug treatment was without further acute effect on dopamine transporter or VMAT-2 function, as assessed 1 h later. Thus, this study describes a model of resistance, possibly explained by: 1) the existence of dopaminergic neurons that are a priori refractory to deficits caused by methamphetamine; 2) the existence of dopaminergic neurons made persistently resistant consequent to a neurotoxic methamphetamine exposure; and/or 3) altered activation of post-synaptic basal ganglia systems necessary for the elaboration of methamphetamine-induced dopamine neurotoxicity.
反复高剂量给予甲基苯丙胺会导致持续性多巴胺能缺陷。由于滥用甲基苯丙胺的个体常常反复接触高剂量药物,因此其反复接触的影响值得研究。相应地,对大鼠进行反复高剂量注射甲基苯丙胺预处理,随后在7天或30天后用相同的神经毒性方案进行“激发”。结果显示,最初的甲基苯丙胺处理导致纹状体多巴胺水平、多巴胺转运体功能和囊泡单胺转运体2功能出现持续性缺陷。在激发后7天评估时,后续的甲基苯丙胺激发处理对这些参数没有进一步的持续性影响,无论初始药物暴露和激发药物暴露之间的间隔时间(7天或30天)如何。同样,在初始药物处理7天后给予甲基苯丙胺激发处理,1小时后评估时,对多巴胺转运体或囊泡单胺转运体2功能没有进一步的急性影响。因此,本研究描述了一种抗性模型,可能的解释为:1)存在对甲基苯丙胺引起的缺陷具有先天抗性的多巴胺能神经元;2)存在因神经毒性甲基苯丙胺暴露而产生持续性抗性的多巴胺能神经元;和/或3)参与甲基苯丙胺诱导的多巴胺神经毒性的突触后基底神经节系统的激活改变。